Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—an European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma

and without dimethyl triazinoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52: 626–632. 11. Gershenson DM, Kavanagh JJ, Copeland LJ et al.. High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer 1987; 59: 1264–1267. 12. Sutton G, Blessing J, Barrett R et al.. Phase II trial of ifosfamide and mesna in leimyosarcoma of the uterus: a Gynecologic Oncologic Group study. Am J Obstet Gynecol 1992; 166: 556–559. 13. Sutton GP, Blessing JA, Rosenheim N et al.. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus. Am J Obstet Gynecol 1989; 161: 309–312. 14. Thigpen JT, Blessing JA, Beecham J et al.. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent uterine sarcomas (a Gynecologic Oncologic Group study). J Clin Oncol 1991; 9: 1962–1966. 15. Thigpen JT, Blessing JA, Orr JW, Jr et al.. Phase II trial of cisplatin in treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncologic Group study. Cancer Treat Rep 1986; 70: 271–274. 16. Piver MS, Deeulis TG, Lele SB et al.. Cyclophosphamide, vincristine, adriamycine, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract. Gynecol Oncol 1982; 14: 319–323. 17. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicine in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 1996; 2: 226–229. 18. Muss HB, Bundy B, disaia PJ et al.. Treatment of recurrent or advanced uterine sarcoma : a randomized trial of doxorubicine versus doxorubicine and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985; 55: 1648–1653. 19. Hensley ML, Maki R, Venkatraman E et al.. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824–2831. 20. Pautier P, Genestie C, Fizazi K et al.. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer 2002; 12: 749–754. 21. Le Cesne A, Antoine E, Spielmann M et al.. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600–1608. 22. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al.. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—an European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150–157. 23. Hempling RE, Piver MS, Baker TR. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (Adriamycine), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. Am J Clin Oncol 1995; 18: 282–286. 24. Buchsbaum HJ, Lifshitz S, Blythe JG. Prophylactic chemotherapy in stages I and II uterine sarcoma. Gynecol Oncol 1979; 8: 346–348. 25. Hannigan EV, Freedman RS, Rutledge FN. Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol 1983; 15: 56–64. 26. Van Nagell JR, Hanson MB, Donaldson ES et al.. Adjuvant vincristine, dactinomycin, and cyclophosphamide in stage I uterine sarcomas: a pilot study. Cancer 1986; 57: 1451–1454. 27. Hensley ML, Ishill N, Soslow R et al.. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009; 112: 563–567.